debate

02/11/2016

Finding a cure: Getting the best Brexit deal for Britain’s life sciences

November 1, 2016

Four months have now elapsed since the UK voted to leave the EU. The wholesale changes to the

Finding a cure: Getting the best Brexit deal for Britain’s life sciences

https://pharmaphorum.com/webinars/finding-cure-getting-best-brexit-deal-britains-life-sciences/

Available on-demand: COPD, connecting real world needs to patient centric solutions

January 19, 2015

COPD is a widespread, costly and largely preventable condition which affects over 300 million people worldwide and

Available on-demand: COPD, connecting real world needs to patient centric solutions

https://pharmaphorum.com/webinars/live-webinar-debate-feb-4th-copd-connecting-real-world-needs-to-patient-centric-solutions-price-is-right-uk-niche-market-access-2/

Available on-demand: The Price is Right? – Delivering UK access for niche patient populations

November 17, 2014

With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what

Available on-demand: The Price is Right? – Delivering UK access for niche patient populations

https://pharmaphorum.com/webinars/live-webinar-the-price-is-right-uk-niche-market-access/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

debate

Finding a cure: Getting the best Brexit deal for Britain’s life sciences

Available on-demand: COPD, connecting real world needs to patient centric solutions

Available on-demand: The Price is Right? – Delivering UK access for niche patient populations

SMi's 12th annual Cold Chain Distribution Conference and Exhibition

RNA Therapeutics 2018

Ophthalmic Drugs - Europe's Leading Ophthalmic Conference

THET Annual Conference 2017

CRISPR & Precision Gene Editing Congress - Berlin 2017

ICI Summit Europe 2017

uniQure presses ‘refresh’ on haemophilia gene therapy, gets FDA blessing

FDA experts back Novo Nordisk’s key diabetes drug

Roche MS drug sales rise, but so does biosimilar threat

Gilead gains CAR-T approval, undercuts rival’s headline price

Lilly joins cancer vaccine race with CureVac alliance

The Patient Summit Europe – Day 1 coverage

Immigration is the Brexit bogeyman, and it’s hurting pharma already

Navigating the barriers to successful market access

Rare disease market research needs a multifaceted approach

What does your pharma brand mean to patients?

Search

Advanced Search

Trending

debate